| CANCER & TREATMENTS SUPPORT & SURVIVORSHIP PREVENTION & RISK ASSESSMENT CLINICAL TRIALS & RESEARCH LIVING WITH CANCER | ||
Home > Newsroom > Publications Michigan Oncology Journal Spring 1999Advancements in Clinical and Basic Science Research from the University of Michigan Comprehensive Cancer CenterContents:The Multidisciplinary Lung Cancer Program Psycho-Oncology Program: Providing Better Emotional Care Bone Metastasis: Approaching an Old Problem in a New Way Of Interest - Clinical Trials and Clinical Services EditorLaurence H. Baker, D.O.Deputy Director and Director for Clinical Research U-M Comprehensive Cancer Center Assistant EditorMaria McKinney WhiteDirector Marketing and Public Relations Home Page:http://www.med.umich.edu/cancerMichigan Oncology Journal From the EditorThe good news is that the incidence of cancer and the resultant mortality has finally begun to decrease in the United States. The recent Tour De France race won by Lance Armstrong - as he won the big race against cancer - again illustrates these successes. Yet still too many patients continue the struggle. Our challenge is to develop new mechanisms to deal with the problems of patients and their families. This issue of the Michigan Oncology Journal describes three new initiatives of our Cancer Center that have been developed over the past year. All three initiatives are multidisciplinary, and all three have very capable and committed leadership. While these three problems are actually quite common among patients with cancer, each has been poorly addressed in our region and indeed in the United States. Greg Kalemkerian, M.D., is a new faculty member to the University of Michigan. Greg and Mark Orringer are the co-directors of our Thoracic Oncology Program, and Greg has led the development of a multidisciplinary lung cancer clinic. This initiative is closely patterned after the successful lung cancer clinic developed at Harper Hospital in Detroit by Manuel Valdivieso, M.D. Greg has identified a team of outstanding clinicians and scientists and will offer state-of-the-art comprehensive care to patients with known or suspected lung cancer. Importantly, they are developing novel diagnostic and therapeutic approaches that will benefit lung cancer patients today and in the future. Michelle Riba, M.D., M.S., is the leader of our new initiative in Psycho-Oncology. The goal of this program is to provide an infrastructure to deliver better emotional care to patients and their families. Depression, anxiety and adjustment problems are common in patients with cancer and their family members. Sometimes cancer treatments such as tamoxifen and interferon will directly cause depression. A new research initiative of this program will explore interferon-induced depression by studying the inter-relationship of emotional distress and interferon levels, as well as serotonin and norepinephrine circulating levels. Portions of the National Comprehensive Cancer Network guidelines developed by Dr. Riba and others to screen for and evaluate emotional distress in patients are also included in this report. Patients with cancers of the lung, breast, prostate and kidney, as well as those with multiple myeloma and non-Hodgkin's lymphoma, sometimes share a common pathway in developing bone metastasis. Often, the clinical manifestations of this metastasis can be severe and debilitating. Yet, only once before (M.D. Anderson Tumor Institute, Houston, Texas) has there been a unified attempt to better diagnose and treat these patients. J. Sybil Biermann, M.D., has led a University of Michigan initiative to form a multidisciplinary clinic to generate concise, comprehensive and complete treatment plans for patients with symptomatic bone metastasis. The intent of this clinic is to provide consultation to oncologists throughout the region so as to improve the quality of care and provide treatment options for patients with bone metastasis by improving pain symptom management and reducing or relieving functional disabilities. It's been fun for me to watch the development of these new activities. I am confident that each will make an important contribution in our struggle against cancer. ![]() Laurence H. Baker, D.O. DirectoryM-LINE - For All Physician Consultation and Referrals1-800-962-3555 The University of Michigan, as an equal opportunity/affirmative action employer, complies with all applicable federal and state laws regarding non-discrimination and affirmative action, including Title IX of the Education Amendments of 1972 and Section 504 of the Rehabilitation Act of 1973. The University of Michigan is committed to a policy of non-discrimination and equal opportunity for all persons regardless of race, sex, color, religion, creed, national origin or ancestry, age, marital status, sexual orientation, disability or Vietnam-era veteran status in employment, educational programs and activities, and admissions. Inquiries or complaints may be addressed to the Universitys Director of Affirmative Action and Title IX/Section 504 Coordinator, 4005 Wolverine Tower, Ann Arbor, Michigan 48109-1281. (734) 763-0235, TDD (734) 747-1388, Fax (734) 763-2891. University of Michigan Information: (734) 764-1817. The University of Michigan Health System is committed to Total Quality. |
Please Note:
This article is from a publication now a part of the Cancer Center's News Archive. It
is listed here for historical purposes only. University of Michigan Comprehensive Cancer Center © 2008 Regents of the University of Michigan / Developed & maintained by: Public Relations & Marketing Communications. Contact Us or UMHS. The information presented is not a tool for self diagnosis or a substitute for professional care. |
||||